Doximity (DOCS +1.30%), a digital platform provider for healthcare professionals, posted impressive fiscal 2025 second-quarter results on Thursday that topped analysts' consensus estimates for revenue and adjusted EPS. Revenue for the quarter ending Sept. 30, 2024, rose 20% to $136.8 million. Adjusted EBITDA of $76.1 million significantly outpaced management's expected $62.5 million to $63.5 million.
Despite macroeconomic challenges, Doximity managed solid operational performance and revenue growth, suggesting a positive outlook.
| Metric | Q2 FY2025 | Analyst Estimates | Q2 FY2024 | Change (YOY) |
|---|---|---|---|---|
| Revenue | $136.8 million | $127.1 million | $113.6 million | 20% |
| Adjusted EBITDA | $76.1 million | N/A | $54.2 million | 41% |
| Net income | $44.2 million | N/A | $30.6 million | 44% |
| Adjusted EPS | $0.30 | $0.26 | $0.22 | 36% |
Source: Doximity. Note: Analyst consensus estimates provided by FactSet. YOY = Year over year. EBITDA = Earnings before interest, taxes, depreciation, and amortization.
Understanding Doximity
Doximity has established itself as the preeminent digital platform connecting U.S. healthcare professionals. By leveraging the vast network of over 2 million members, including more than 80% of U.S. physicians, it enhances how medical professionals interact and collaborate. Doximity offers tools that facilitate telehealth services, secure communications, and comprehensive digital marketing solutions for pharmaceutical manufacturers and health systems.
Doximity is concentrating on growing its network and advancing its productivity solutions. Tools like its telehealth services and artificial intelligence (AI)-based administrative assistants, including Doximity GPT, have been key in embedding the platform into daily medical workflows.
NYSE: DOCS
Key Data Points
Quarterly Performance Highlights
The 20% year-over-year increase in revenue was primarily due to greater adoption of its productivity tools and expanded reach among healthcare professionals. Adjusted EBITDA hit $76.1 million, indicating robust operational efficiency with a 41% increase from the previous quarter's result of $54.2 million. Adjusted EPS was up 36% and exceeded estimates for the quarter.
Financial execution was complemented by high levels of engagement, notably with its clinical tools, utilized by over 600,000 unique prescribers. Doximity's expanded product reach and continued focus on user engagement have been critical success drivers. The fiscal quarter also saw a remarkable 44% growth in net income, reaching $44.2 million.
However, Doximity acknowledges the macroeconomic uncertainties looming on the horizon. In its first-quarter earnings call, the firm highlighted potential challenges related to broader economic volatility and competitive pressures. It maintains a cautious outlook, planning for additional product rollouts, particularly around its AI offerings, which are critical to maintaining its competitive position.
Strategic Outlook
For the fiscal third quarter (ending Dec. 31, 2024), Doximity expects revenue between $152 million and $153 million and adjusted EBITDA between $83 million and $84 million. For the full fiscal 2025 (ending in March 2025), Doximity boosted its revenue projection to a range between $535 million and $540 million from a previous estimate of $506 million-to-$518 million. That revenue is expected to lead to adjusted EBITDA between $274 million and $279 million. This indicates continued confidence in demand for its services, despite external economic pressures.
Investors should keep an eye on Doximity's planned advancements in its platform, especially its AI and data analytics capabilities. These innovations remain crucial to the company's strategy of expanding its market reach and enhancing customer value. While managing macroeconomic risks and execution strategies for new product launches will require attention, Doximity's trajectory remains promising for the coming quarters.
